白蛋白结合型紫杉醇与SPARC蛋白在乳腺癌中的进展
Progression of Albumin-Bound Paclitaxel and SPARC Protein in Breast Cancer
DOI: 10.12677/ACM.2021.1111782, PDF,   
作者: 张 兰：青海大学研究生院，青海 西宁；姜 军：青海大学附属肿瘤医院肿瘤内科，青海 西宁
关键词: 白蛋白结合型紫杉醇；SPARC蛋白；乳腺癌；Albumin-Bound Paclitaxel； SPARC Protein； Breast Cancer
摘要: 紫杉醇类抗肿瘤药物包括紫杉醇、多西他赛、紫杉醇脂质体、白蛋白结合型紫杉醇(nab-PTX)。用于多种恶性肿瘤，其属于新型抗微管药物。随着紫杉醇药物的研究进展，药物的缺点在不断改善。白蛋白结合型紫杉醇(nab-PTX)是一种利用纳米技术将紫杉醇药物与白蛋白结合起来的第一个被批准上市的纳米微粒型，无需特殊溶剂，使用方便、毒性反应小、增加抗肿瘤活性。SPARC蛋白是由肿瘤细胞分泌到肿瘤间质结合白蛋白的蛋白。本文主要综述白蛋白结合型紫杉醇与SPARC蛋白在乳腺癌中的研究进展。
Abstract: Paclitaxel antitumor drugs include paclitaxel, docetaxel, paclitaxel liposomes, and albumin-bound paclitaxel (NAB-PTX). For a variety of malignant tumors, it belongs to the new anti-microtubule drugs. With the development of paclitaxel drugs, the shortcomings of drugs are improving. Albumin-bound paclitaxel (NAB-PTX) is a nanoparticle that combines the drug paclitaxel with albumin and is the first to be approved for marketing. It requires no special solvent, is easy to use, has low toxicity and increases anti-tumor activity. SPARC protein is secreted by tumor cells into tumor interstitial binding albumin. This review focuses on the research progress of albumin-bound paclitaxel and SPARC protein in breast cancer.
文章引用：张兰, 姜军. 白蛋白结合型紫杉醇与SPARC蛋白在乳腺癌中的进展[J]. 临床医学进展, 2021, 11(11): 5295-5298. https://doi.org/10.12677/ACM.2021.1111782

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. [Google Scholar] [CrossRef] [PubMed]
[3] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
[4] Azim, H.A., Singhal, S., Ignatiadis, M., et al. (2013) Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in early Breast Cancer: A Pooled In-Silico Analysis. PLoS ONE, 8, e62451. [Google Scholar] [CrossRef] [PubMed]
[5] Wu, X.L., Tu, Q., Faure, G., et al. (2016) Diagnostic and Prognostic Value of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. Scientific Reports, 6, Article No. 20210. [Google Scholar] [CrossRef] [PubMed]
[6] Mauzo, S.H., Milton, D.R., Prieto, V.G., et al. (2018) Summary of Expression of SPARC Protein in Cutaneous Vascular Neoplasms and Mimickers. Annals of Diagnostic Pathology, 34, 151-154. [Google Scholar] [CrossRef] [PubMed]
[7] Sangaletti, S., Talarico, G., Chiodoni, C., et al. (2019) SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. Frontiers in Immunology, 10, 1369. [Google Scholar] [CrossRef] [PubMed]
[8] Sun, W., Feng, J., Yi, Q., et al. (2018) SPARC Acts as a Mediator of TGF-beta1 in Promoting Epithelial-to-Mesenchymal Transition in A549 and H1299 Lung Cancer Cells. Biofactors, 44, 453-464. [Google Scholar] [CrossRef] [PubMed]
[9] Lindner, J.L., Loibl, S., Denkert, C., et al. (2015) Expression of Secreted Protein Acidic and Rich in Cysteine (SPARC) in Breast Cancer and Response to Neoadjuvant Chemotherapy. Annals of Oncology, 26, 95-100. [Google Scholar] [CrossRef] [PubMed]
[10] Goyal, S., Oak, E., Luo, J., et al. (2018) Minimal Activity of Nanoparticle Albumin-Bound (nab) Paclitaxel in Relapsed or Refractory Lymphomas: Results of a Phase-I Study. Leukemia & Lymphoma, 59, 357-362. [Google Scholar] [CrossRef] [PubMed]
[11] Paik, P.K., James, L.P., Riely, G.J., et al. (2011) A Phase 2 Study of Weekly Albumin-Bound Paclitaxel (Abraxane®) Given as a Two-Hour Infusion. Cancer Chemotherapy and Pharmacology, 68, 1331-1337. [Google Scholar] [CrossRef] [PubMed]
[12] Carver, L.A. and Schnitzer, J.E. (2003) Caveolae: Mining Little Caves for New Cancer Targets. Nature Reviews Cancer, 3, 571-581. [Google Scholar] [CrossRef] [PubMed]
[13] Koblinski, J.E., Kaplan-Singer, B.R., Van Osdol, S.J., et al. (2005) Endogenous Osteonectin/SPARC/BM-40 Expression Inhibits MDA-MB-231 Breast Cancer Cell Metastasis. Cancer Research, 65, 7370-7377. [Google Scholar] [CrossRef] 
[14] Gilles, C., Bassuk, J.A., Pulyaeva, H., et al. (1998) SPARC/Osteonectin Induces Matrix Metalloproteinase 2 Activation in Human Breast Cancer Cell Lines. Cancer Research, 58, 5529-5536.
[15] 徐东旭, 徐璐, 李彦君, 等. SPAＲC 蛋白在乳腺癌组织中的表达及临床意义[J]. 中国医科大学学报, 2014, 44(6): 493-498.
[16] 闫成, 洪伟. 乳腺癌组织中SPARC蛋白的表达观察[J]. 山东医药, 2016, 56(11): 63-64.
[17] Nagai, M.A., Gerhard, R., Fregnani, J.H., et al. (2011) Prognostic Value of NDRG1 and SPARC Protein Expression in Breast Cancer Patients. Breast Cancer Research and Treatment, 126, 1-14. [Google Scholar] [CrossRef] [PubMed]
[18] Yang, M., Qu, H., Liu, A., et al. (2019) Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer. Journal of Cancer Research and Therapeutics, 15, 1561-1566. [Google Scholar] [CrossRef] 

为你推荐